Thyroid Nodule Biopsy Results Explained: What's Normal and What's Not
By Hanna Söderqvist|Updated Oct 06, 2026|6 min read
A thyroid fine-needle aspiration comes back as a category rather than a number, and each category points toward a different next step with your care team.
A thyroid nodule biopsy — usually a fine-needle aspiration, or FNA, in which a thin needle draws cells from a lump in the thyroid gland at the base of your neck — does not produce a single number like a cholesterol level. The cells are read under a microscope and sorted into a category, and that category carries an estimated chance that the nodule is cancer.
This guide explains the categories most US labs use, what commonly shifts a result for reasons other than disease, and what to ask at your next appointment. It is general information, not a reading of your report.
What This Test Measures
The pathologist (a doctor who examines tissue and cells) is judging the appearance of thyroid cells, not measuring a chemical. Instead of a value in mg/dL or ng/mL, each category is paired with an estimated risk of malignancy — the chance the nodule is cancerous — expressed as a percentage (%).
Result Range
What It May Indicate
Typical Next Step
Nondiagnostic or unsatisfactory, roughly 1–4% risk of malignancy (American Journal of Roentgenology, undated)
Too few cells to make a diagnosis, often because only cyst fluid or excess blood was drawn (American Thyroid Association, undated)
Repeat FNA; if nondiagnostic again, a third biopsy, monitoring or surgery is considered
Benign, under about 3% risk of malignancy; up to 70% of biopsies fall here (American Thyroid Association, undated)
Cells look like ordinary thyroid tissue
Generally a follow-up ultrasound within 18 months
Atypia or follicular lesion of undetermined significance (AUS/FLUS) — "indeterminate" — about 5–15% risk (American Thyroid Association, undated)
Some cells look unusual but not enough to classify
Repeat biopsy and/or molecular (gene) testing may be useful
Follicular neoplasm or suspicious for follicular neoplasm — also "indeterminate" — about 15–30% risk (American Thyroid Association, undated)
Pattern that often cannot be called benign or malignant unless the nodule is removed
Molecular testing and/or surgical removal is discussed
Suspicious for malignancy, about 60–75% risk (American Thyroid Association, undated)
Worrisome features that fall short of diagnostic
Surgery is the typical path
Malignant, 97–99% chance the lesion is truly cancerous; 3–7% of all specimens (American Thyroid Association, undated)
Cells meet criteria for thyroid cancer
Almost all of these nodules go to surgery
These percentages are category-level estimates, not personal odds, and the American Thyroid Association notes they can differ between institutions and centers. About 25% of samples land in the two indeterminate categories, with malignancy risk spanning 5% to 30% (American Academy of Family Physicians, 2020). Your doctor reads the category alongside your ultrasound, thyroid blood tests, history and exam.
What Can Affect Your Result
Several things other than the nature of the nodule itself can change what the pathologist sees:
Cyst fluid in the nodule. In a study of 1,458 thyroid nodule FNAs, cystic content was the only significant independent predictor of a nondiagnostic result (PubMed study abstract, undated).
Blood in the specimen. Excess blood can obscure or dilute the cells and lead to a nondiagnostic report (American Thyroid Association, undated).
Prior radioactive iodine (131I) therapy. In a study of 4,018 thyroid FNA biopsies, past 131I treatment was a statistically significant risk factor for a repeat nondiagnostic result (PubMed study abstract, undated).
Which part of the nodule the needle reaches. Sampling and the number of needle passes influence how representative the cells are; an extra pass is sometimes taken for molecular testing (American Thyroid Association, undated).
Which lab or institution reads the slide. Category definitions are shared, but the malignancy percentages quoted for each one vary by center (American Thyroid Association, undated).
Your medications, including blood thinners. Cleveland Clinic advises asking your provider whether any medication should be paused in the days before the procedure — that is their call, not something to change on your own (Cleveland Clinic, undated).
Soreness and bruising afterward, which Cleveland Clinic lists as common and usually manageable with over-the-counter pain relief such as acetaminophen (Tylenol), do not affect the cytology result, though rare complications include bleeding, infection and cyst formation (Cleveland Clinic, undated).
Questions to Ask Your Doctor About This Result
Bring the report itself. Ask in this order:
"Which Bethesda category is my result, and what does that category mean when you put it together with my ultrasound and thyroid blood tests?"
"What cancer risk does the lab that read my slide attach to this category, and how confident are they in the sample quality?"
"Would molecular or genetic testing on my sample change the plan, and would that need another needle pass?"
"What is the next test or monitoring step — a repeat biopsy, a repeat ultrasound, a core needle biopsy, or a surgical referral — and when should it happen?"
"If we monitor instead of act now, what would make you change course before the next scheduled scan?"
"Which symptoms should make me call your office the same day?"
On that last point: get medical help the same day for a rapidly swelling neck, a hoarse voice that comes on suddenly, or fever after a biopsy, and call 911 for trouble breathing or swallowing.
Frequently asked questions
How long do thyroid biopsy results take?
The American Thyroid Association notes it generally takes anywhere from a few days to two weeks for results to return. If molecular testing is added, the wait can be longer. Ask the office that performed the biopsy how results will reach you and who will explain them — that is your doctor, who has your full history and other results.
Does a repeat biopsy mean something is wrong?
A repeat FNA is the standard response to a nondiagnostic sample, which usually reflects the cells collected rather than the nodule's nature. In one study summary reported by the American Thyroid Association, repeat FNA was obtained in 85.5% of such nodules and was benign in 73% of those repeated, and a separate study found a diagnostic result on the first repeat in 63% of cases. What your own repeat means is for your doctor, who has your full history and other results.
What is molecular testing, and does it replace surgery?
Molecular testing looks at genes within the nodule's cells and is used when cytology is indeterminate (American Thyroid Association, undated). A review article in PMC reports that third-generation tests show negative predictive values of 90–100% and surgical avoidance rates of 50.3–68.6% in indeterminate cytology, while the American Academy of Family Physicians notes that a benign molecular pattern lowers risk but these nodules still need ultrasound surveillance. Whether it fits your situation is a conversation with your doctor, who has your full history and other results.
What is a core needle biopsy?
A core needle biopsy uses a slightly larger needle to take a small tissue core rather than loose cells, and MyHealth Alberta notes it may be done when fine-needle results are uncertain. It is not routinely used first in every center. Whether it would add anything for you is a question for your doctor, who has your full history and other results.
Hanna writes about the quieter corners of mental health: boredom, loneliness, the ordinary weight of being tired. She approaches the subject with patience, resisting easy resolutions in favor of honest complication.
